Hypogonadotropic Hypogonadism/Kallmann Syndrome Panel
Use
This test is designed for individuals who have relevant features or a clinical or suspected diagnosis of hypogonadotropic hypogonadism or Kallmann syndrome. It is particularly useful for those experiencing absent or incomplete puberty accompanied by low levels of gonadotropins such as LH and FSH.
Special Instructions
New York approved. Exome and genome platforms are available for order. Family testing options, such as targeted family testing, are also offered.
Limitations
This test is developed and validated by PreventionGenetics following CAP and CLIA regulations but is not cleared or approved by the FDA. It combines NGS sequencing with CNV analysis but may not detect all genetic alterations. Results should be interpreted in the context of clinical symptoms and other laboratory findings.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided